title: [Pharmacokinetic and clinical studies of sultamicillin fine granules in children].
abstract: Sultamicillin (SBTPC) is a semi-synthesized beta-lactam antibiotic consisted of ampicillin (ABPC) and a beta-lactamase inhibitor, sulbactam (SBT), linked with an ester linkage. Pharmacokinetic and clinical studies using SBTPC 10% fine granules were performed in pediatric patients with a variety of infections. 1. Pharmacokinetic investigation: SBTPC was given at 30 minutes after meal at a dose of 10 mg/kg. Peak serum levels were attained at 1 hour after dosing with average levels of 3.83 +/- 0.27 micrograms/ml for ABPC and 2.73 +/- 0.30 micrograms/ml for SBT. The average half-life of ABPC was 1.52 +/- 0.25 hours and that of SBT was 1.13 +/- 0.09 hours. The urinary recovery rate of ABPC during 6 hours after dosing was 58.2 +/- 4.9% and that of SBT was 59.7 +/- 6.4%. 2. Clinical investigation: Enrolled in the study were a total of 26 patients including 12 with tonsillitis, 6 with pharyngitis, 5 with urinary tract infections, and 1 each with bronchitis, with Salmonella enteritis and a case with fever of unknown case. Responses were excellent in 15 patients, good in 8, fair in 2 and poor in 1 with an efficacy rate of 88.5%. In the assessment of the bacteriological efficacy, 11 out of 14 strains of organisms isolated previous to the treatment were eradicated, 1 strain was found reduced in number and 2 strains remained unchanged with an eradication rate of 78.6%. One patient (3.8%) out of the 26 had diarrhea as side effects and 3 patients (16.7%) of 18 showed eosinophilia in laboratory examinations.
authors.affiliation: Department of Pediatrics, School of Medicine, Nagasaki University.
authors.forename: M
authors.initials: M
authors.lastname: Yanagishima
authors.forename: M
authors.initials: M
authors.lastname: Yanai
authors.forename: T
authors.initials: T
authors.lastname: Yanagi
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuji
authors.forename: H
authors.initials: H
authors.lastname: Imamura
authors.forename: N
authors.initials: N
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000667:Ampicillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004304:Dosage Forms; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D013407:Sulbactam / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D004304:Dosage Forms; C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam